Nickan Research Institute Journal of Parathyroid Disease 2345-6558 5 1 2017 01 01 Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients 17 24 EN Usman Kahlid Cheema Armughan Ahmed Chaudhary Muhammad Junaid Nazar Ghias Uddin Butt Aftab Cheema Muhammad Bilal Aisha Ashraf Journal Article Introduction: Hyperphosphatemia is also known as a silent killer among patients with renal failure. Objectives: The objectives of this investigation was to assess the efficiency and tolerability of sevelamer in hyperphosphatemia in Pakistani patients on regular hemodialysis. Patients and Methods: A total of 59 dialysis individuals (age >18 years), from both genders, on regular hemodialysis with phosphate level more than 5.5 mg/dL, not on any phosphate binders was enrolled to the study. All the patients received sevelamer 400 mg orally in a dose depending on their baseline serum phosphorus level. Patients received the treatment for duration of 8 weeks. All the patients were followed and investigated for the efficacy and safety variables on fortnightly basis. Results: The mean (± SD) age of all the enrolled patients was 42.2 (±6.4) years. The mean (±SD) serum phosphorus was reduced significantly to 6.70 (±0.86) mg/dL, 6.00 (±0.64) mg/dL, 5.30 (±0.87) mg/dL and 4.97 (±0.91) mg/dL on day 15 (P < 0.0001), 30 (P < 0.0001), 45 (P < 0.0001) and day 60 (P < 0.0001) respectively. The mean (SD) serum total cholesterol was also reduced non-significantly to 193.9 (±15.6) mg/dL, significantly to 192.1 (±15.9) mg/dL, to 190.6 (±17.0) mg/dL and to 188.1 (±16.3) mg/dL on day 15 (P = 0.085), day 30 (P = 0.003), day 45 (P < 0.0001), and on day 60 (P < 0.0001) respectively. Conclusion: Our study showed a significant reduction in mean serum phosphorus and total cholesterol, in patients on hemodialysis. Therefore, sevelamer is a safe drug for the treatment of hyperphosphatemia in our clinical settings.